← Back to Screener
CVRx, Inc. Common Stock (CVRX)
Price$7.24
Favorite Metrics
Price vs S&P 500 (26W)-26.51%
Price vs S&P 500 (4W)-24.80%
Market Capitalization$193.65M
All Metrics
Book Value / Share (Quarterly)$1.49
P/TBV (Annual)3.82x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)36.10%
Cash Flow / Share (Quarterly)$-1.55
Price vs S&P 500 (YTD)-0.48%
Gross Margin (TTM)85.33%
Net Profit Margin (TTM)-94.10%
EPS (TTM)$-2.04
10-Day Avg Trading Volume0.30M
EPS Excl Extra (TTM)$-2.04
Revenue Growth (5Y)56.42%
EPS (Annual)$-2.04
ROI (Annual)-60.00%
Gross Margin (Annual)85.33%
Net Profit Margin (5Y Avg)-166.12%
Cash / Share (Quarterly)$2.88
Revenue Growth QoQ (YoY)4.45%
ROA (Last FY)-50.87%
Revenue Growth TTM (YoY)10.45%
EBITD / Share (TTM)$-1.79
ROE (5Y Avg)-68.33%
Operating Margin (TTM)-90.49%
Cash Flow / Share (Annual)$-1.55
P/B Ratio4.92x
P/B Ratio (Quarterly)4.73x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.96x
Net Interest Coverage (TTM)-8.15x
ROA (TTM)-45.83%
EPS Incl Extra (Annual)$-2.04
Current Ratio (Annual)7.63x
Quick Ratio (Quarterly)6.49x
3-Month Avg Trading Volume0.31M
52-Week Price Return19.67%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.98
P/S Ratio (Annual)3.42x
Asset Turnover (Annual)0.54x
52-Week High$11.30
Operating Margin (5Y Avg)-137.77%
EPS Excl Extra (Annual)$-2.04
CapEx CAGR (5Y)13.35%
26-Week Price Return-17.77%
Quick Ratio (Annual)6.49x
13-Week Price Return21.65%
Total Debt / Equity (Annual)1.26x
Current Ratio (Quarterly)7.63x
Enterprise Value$167.459
Revenue / Share Growth (5Y)47.26%
Asset Turnover (TTM)0.49x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.68x
Pretax Margin (Annual)-94.13%
Cash / Share (Annual)$2.88
3-Month Return Std Dev88.47%
Gross Margin (5Y Avg)80.60%
Net Income / Employee (TTM)$-0
ROE (Last FY)-135.56%
Net Interest Coverage (Annual)-8.15x
EPS Basic Excl Extra (Annual)$-2.04
Receivables Turnover (TTM)5.68x
Total Debt / Equity (Quarterly)1.26x
EPS Incl Extra (TTM)$-2.04
Receivables Turnover (Annual)5.68x
ROI (TTM)-51.71%
P/S Ratio (TTM)3.42x
Pretax Margin (5Y Avg)-165.79%
Revenue / Share (Annual)$2.17
Tangible BV / Share (Annual)$5.29
Price vs S&P 500 (52W)-15.42%
Year-to-Date Return3.66%
5-Day Price Return-5.76%
EPS Normalized (Annual)$-2.04
ROA (5Y Avg)-38.60%
Net Profit Margin (Annual)-94.10%
Month-to-Date Return-22.20%
Cash Flow / Share (TTM)$-2.03
EBITD / Share (Annual)$-1.79
Operating Margin (Annual)-90.49%
LT Debt / Equity (Annual)1.26x
ROI (5Y Avg)-42.85%
LT Debt / Equity (Quarterly)1.26x
EPS Basic Excl Extra (TTM)$-2.04
P/TBV (Quarterly)5.03x
P/B Ratio (Annual)4.73x
Inventory Turnover (TTM)0.68x
Pretax Margin (TTM)-94.13%
Book Value / Share (Annual)$1.49
Price vs S&P 500 (13W)18.79%
Beta0.88x
Revenue / Share (TTM)$2.16
ROE (TTM)-99.33%
52-Week Low$4.30
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
CVRXCVRx, Inc. Common Stock | 3.42x | 56.42% | 85.33% | -90.49% | $7.24 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
CVRx Inc is a commercial-stage medical device company developing minimally invasive neuromodulation solutions for heart failure and other cardiovascular diseases. Its proprietary Barostim platform uses Baroreflex Activation Therapy to restore autonomic nervous system balance and improve cardiac function. The company generates revenue primarily from the U.S. market.